It works by targeting the brains hypothalamus, altering hunger signals and enhancing feelings of fullness, which supports healthier eating habits and reduces overall calorie intake
When biosimilar GLP-1 medications reach the US market, the implications will be significant: Insurance coverage will restructure Payers will likely mandate biosimilar substitution for new GLP-1 prescriptions, similar to what occurred with insulin biosimilars and adalimumab (Humira) Manufacturing access will widen Companies including Biocon, Zydus Lifesciences, and Teva are actively building production capacity
We see this same pattern after: Bariatric surgery Severe calorie restriction Illness or hospitalization Postpartum hormone shifts GLP-1 therapy can create a similar metabolic environment if weight loss is aggressive or nutrition is inadequate
The medications arent designed for people who just want to lose a few pounds
How to Make the Switch: Step-by-Step Moving from one medicine to a new one takes a careful plan
How is it different from other weight loss drugs